Patents by Inventor Jessica Kollmeyer

Jessica Kollmeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of reducing accumulation of intracellular tingible body macrophages
    Patent number: 10111937
    Abstract: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: October 30, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu
  • Lysosomal Phospholipase A2 (LPLA2) Activity as a Diagnostic and Therapeutic Target for Identifying and Treating Systemic Lupus Erythematosus
    Publication number: 20160317626
    Abstract: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
    Type: Application
    Filed: April 11, 2016
    Publication date: November 3, 2016
    Inventors: James A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu
  • Lysosomal phospholipase A2 (LPLA2) activity as a therapeutic target for treating systemic lupus erythematosus
    Patent number: 9309553
    Abstract: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: April 12, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu
  • Lysosomal Phospholipase A2 (LPLA2) Activity as a Diagnostic and Therapeutic Target for Identifying and treating Systemic Lupus Erythematosis
    Publication number: 20120121571
    Abstract: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
    Type: Application
    Filed: October 13, 2011
    Publication date: May 17, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu
  • Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
    Patent number: 8052970
    Abstract: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: November 8, 2011
    Assignee: The Regents of the University of Michigan
    Inventors: James A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu
  • LYSOSOMAL PHOSPHOLIPASE A2 (LPLA2) ACTIVITY AS A DIAGNOSTIC AND THERAPEUTIC TARGET FOR IDENTIFYING AND TREATING SYSTEMIC LUPUS ERYTHEMATOSIS
    Publication number: 20090324575
    Abstract: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
    Type: Application
    Filed: June 30, 2009
    Publication date: December 31, 2009
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu